Business
Ocumetics Announces Appointment of Dr. Doyle Stulting as Chief Medical Officer
(TheNewswire) Calgary, Alberta - TheNewswire – October 18 ...
About this update from Ocumetics Technology Corp
[{"type":"text","content":"Ocumetics Announces Appointment of Dr. Doyle Stulting as Chief Medical Officer\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n Calgary, Alberta -\n \n \n TheNewswire\n \n \n –\nOctober 18\n \n \n , 2021\n \n \n .\n Ocumetics Technology Corp. (formerly Quantum Blockchain Technologies\nLtd.) (\n \n \n TSXV:OTC) (“\n \n \n Ocumetics\n \n \n ”) is\npleased to announce that it has appointed Doyle Stulting, M.D., Ph.D,\nas its Chief Medical Officer.\n \n \n \n \n “We are thrilled to have Dr. Stulting join our\nteam,” says Dr. Mark Lee, President and CEO of Ocumetics. “As\nChief Medical Officer of Ocumetics, Dr. Stulting will draw from his\nextensive experience to lead the company through our upcoming clinical\ntrials. Together with Dr. Garth Webb, our Chief Scientific Officer and\nthe inventor of the Bionic Lens, Dr. Stulting will be instrumental in\nthe process of gaining regulatory approval of the Bionic Lens in\nmultiple countries and bringing the Bionic Lens to full\ncommercialization.”\n \n \n \n \n Dr. Doyle Stulting is Director of the Stulting Research\nCenter, Woolfson Eye Institute, Atlanta, GA, Professor of\nOphthalmology Emeritus, Emory University, and Adjunct Professor of\nOphthalmology, the Moran Eye Institute, Salt Lake City, UT.\n \n \n \n \n Dr. Stulting began his career with basic research in\nherpetic ocular infections and corneal transplant immunology. He was\nCo-Director of the Collaborative Corneal Transplantation Studies, a\nlarge, NIH-supported multi-center study of histocompatibility and\ncorneal transplantation. He then turned his attention to refractive\nsurgery, as an investigator in a physician-sponsored clinical\ninvestigation of LASIK that was carried out before the first\nrefractive laser was approved by the FDA in the United States.  He\nhas had a referral practice in cornea/external disease and performed\nroutine and complex cataract surgery, as well as corneal\ntransplantation until January 2019, when he began to specialize in the\nmanagement of keratoconus. Dr. Stulting has been Principal\nInvestigator for 5 different clinical trials for corneal crosslinking\nsince 2008.\n \n \n \n \n For ten years, Dr. Stulting was a member of the FDA\nOphthalmic Devices Panel, and he completed a term as Chair of the\nPanel in 1998.  He is Past Presiden...